Lipitor Switch Decision Could Portend Pfizer’s Consumer Product Future

As CEO Ian Read leaves open a door for the firm to unload the consumer business, industry consultant Steve Francesco says Pfizer’s decision to end its Lipitor switch program could move the business out the door.